

*Additional Letters:* There were three additional letters that did not contain comments. They asked questions that were answered in the text of this Notice or required very detailed responses that were more appropriate for response in technical assistance meetings.

Dated: May 17, 2012.

**Mary K. Wakefield,**  
Administrator.

[FR Doc. 2012-12568 Filed 5-22-12; 8:45 am]

**BILLING CODE 4165-15-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Proposed Collection; Comment Request; Cognitive Testing of Instrumentation and Materials for the Population Assessment of Tobacco and Health (PATH) Study**

**SUMMARY:** In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995,

for opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

*Proposed Collection: Title:* Cognitive Testing of Instrumentation and Materials for Population Assessment of Tobacco and Health (PATH) Study.

*Type of Information Collection Request:* Generic Clearance. *Need and Use of Information Collection:* The PATH study will establish a population-based framework for monitoring and evaluating the behavioral and health impacts of regulatory provisions implemented as part of the Family Smoking Prevention and Tobacco Control Act (FSPTCA) by the Food and Drug Administration (FDA). NIDA is requesting generic approval from OMB for cognitive testing of the PATH study's instrumentation, materials to support data collection (e.g., advance mailings,

reminder letters, etc.), consent forms, and methods of administration (e.g., computer assisted personal interviews [CAPI], audio computer assisted self-interviews [ACASI], web-based interviews). Cognitive testing of these materials and methods will help to ensure that their design and content are valid and meet the PATH study's objectives. Additionally, results from cognitive testing will inform the feasibility (scientific robustness), acceptability (burden to participants and study logistics) and cost of the information collection to help minimize its estimated cost and public burden.

*Frequency of Response:* Annual [As needed on an on-going and concurrent basis]. *Affected Public:* Members of the public. *Type of Respondents:* Youth (ages 12-17) and Adults (ages 18+). *Annual Reporting Burden:* See Table 1. The annualized cost to respondents is estimated at: \$11,861. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

**TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN SUMMARY—COGNITIVE TESTING OF INSTRUMENTATION AND MATERIALS FOR THE PATH STUDY**

Instruments/Documents to be tested	Type of respondent	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response*	Estimated total annual burden hours requested
Materials to Support Data Collection .....	Adult .....	100	1	1 <sup>30/60</sup>	150
Assent Forms .....	Youth .....	98	1	2	196
Consent Forms .....	Adult .....	98	1	2	196
PATH Study Questionnaires .....	Youth .....	40	1	2	80
	Adult .....	130	1	2	260
<b>Total .....</b>		<b>466</b>			<b>882</b>

\* Calculations include one hour of travel time per respondent.

*Request for Comments:* Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the data collection plans contact Kevin P. Conway, Ph.D., Deputy Director, Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, 6001 Executive Blvd., Room 5185, Rockville, MD 20852, or call non-toll free number 301-443-8755 or Email your request, including your address to:  
[PATHprojectofficer@mail.nih.gov](mailto:PATHprojectofficer@mail.nih.gov).

*Comments Due Date:* Comments regarding this information collection are best assured of having their full effect if received within 60-days of the date of this publication.

Dated: May 17, 2012.

**David Shurtleff,**

Acting Deputy Director, NIDA.

[FR Doc. 2012-12489 Filed 5-22-12; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Center for Scientific Review Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR Panel: Selected Topics in Transfusion Medicine.

*Date:* June 12–13, 2012.

*Time:* 11 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Bukhtiar H Shah, DVM, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4120, MSC 7802, Bethesda, MD 20892, (301) 301 806–7314, [shahb@csr.nih.gov](mailto:shahb@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Regulatory Genomics.

*Date:* June 13, 2012.

*Time:* 12 p.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Richard A Currie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1108, MSC 7890, Bethesda, MD 20892, (301) 435–1219, [currieri@csr.nih.gov](mailto:currieri@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Drug Discovery for the Nervous System: Quorum.

*Date:* June 14–15, 2012.

*Time:* 8 a.m. to 10 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Mayflower Park Hotel, 405 Olive Way, Seattle, WA 98101.

*Contact Person:* Mary Custer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7850, Bethesda, MD 20892, (301) 435–1164, [custerm@csr.nih.gov](mailto:custerm@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Collaborative Applications: Sleep and Mood Disorders.

*Date:* June 15, 2012.

*Time:* 9 a.m. to 10 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Morrison Clark Hotel, 1015 L Street NW., Washington, DC 20001.

*Contact Person:* Maribeth Champoux, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3170, MSC 7848, Bethesda, MD 20892, 301–594–3163, [champoum@csr.nih.gov](mailto:champoum@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR12–010: RES. Relevant to the Family Smoking, Prevention/Tobacco Control Act.

*Date:* June 15, 2012.

*Time:* 10 a.m. to 12 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Marriott Copley Place Hotel, 110 Huntington Avenue, Boston, MA 02116.

*Contact Person:* Everett E Sinnett, Ph.D., Scientific Review Officer, Center for

Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2178, MSC 7818, Bethesda, MD 20892, 301–435–1016, [sinnett@nih.gov](mailto:sinnett@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; RFA Panel: Molecular Probes.

*Date:* June 15, 2012.

*Time:* 10:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Mayflower Park Hotel, 405 Olive Way, Seattle, WA 98101.

*Contact Person:* Mary Custer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7850, Bethesda, MD 20892, (301) 435–1164, [custerm@csr.nih.gov](mailto:custerm@csr.nih.gov).

*Name of Committee:* Vascular and Hematology Integrated Review Group; Hemostasis and Thrombosis Study Section.

*Date:* June 18, 2012.

*Time:* 8 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* InterContinental Chicago Hotel, 505 North Michigan Avenue, Chicago, IL 60611.

*Contact Person:* Bukhtiar H Shah, Ph.D., DVM, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4120, MSC 7802, Bethesda, MD 20892, (301) 435–1233, [shahb@csr.nih.gov](mailto:shahb@csr.nih.gov).

*Name of Committee:* Digestive, Kidney and Urological Systems Integrated Review Group; Kidney Molecular Biology and Genitourinary Organ Development.

*Date:* June 18, 2012.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Avenue Hotel Chicago, 160 E. Huron Street, Chicago, IL 60611.

*Contact Person:* Ryan G Morris, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4205, MSC 7814, Bethesda, MD 20892, 301–435–1501, [morrisr@csr.nih.gov](mailto:morrisr@csr.nih.gov).

*Name of Committee:* Biobehavioral and Behavioral Processes Integrated Review Group; Child Psychopathology and Developmental Disabilities Study Section.

*Date:* June 18–19, 2012.

*Time:* 8 a.m. to 11 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Fairmont Washington, DC, 2401 M Street NW., Washington, DC 20037.

*Contact Person:* Jane A Doussard-Roosevelt, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, MSC 7848, Bethesda, MD 20892, (301) 435–4445, [doussarj@csr.nih.gov](mailto:doussarj@csr.nih.gov).

*Name of Committee:* Healthcare Delivery and Methodologies Integrated Review Group; Community-Level Health Promotion Study Section.

*Date:* June 18–19, 2012.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Ritz Carlton Hotel, 1150 22nd Street NW., Washington, DC 20037.

*Contact Person:* Jacinta Bronte-Tinkew, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3164, MSC 7770, Bethesda, MD 20892, (301) 806–0009, [brontetinkewjm@csr.nih.gov](mailto:brontetinkewjm@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Genitourinary Organ Development.

*Date:* June 18, 2012.

*Time:* 12 p.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

*Contact Person:* Patricia Greenwel, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2178, MSC 7818, Bethesda, MD 20892, 301–435–1169, [greenwep@csr.nih.gov](mailto:greenwep@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: May 17, 2012.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2012–12519 Filed 5–22–12; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Heart, Lung, and Blood Initial Review Group; Heart, Lung, and Blood Program Project Review Committee.

*Date:* June 15, 2012.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Jeffrey H Hurst, Ph.D., Scientific Review Officer, Office of Scientific